Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a smartphone app break the stigma barrier to HIV prevention?

NCT ID NCT06576648

Prevention Sponsor: University of Massachusetts, Worcester Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 01, 2026 · Updated 3 times

Summary

This study is testing a mobile app designed to help young Thai adults (ages 18-29) overcome stigma and start or stick with HIV prevention pills (PrEP). The app uses motivational interviewing and tailored content delivered over four sessions. Researchers will enroll 154 participants to see if the app is acceptable, feasible, and can improve PrEP use and reduce stigma.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Mobile app with motivational interviewing sessions
What this could lead to
If successful, this could provide an effective, scalable way to increase HIV prevention pill use among young people facing stigma.
What could go wrong
This is a small, early-stage trial focused on feasibility and acceptability, not on proving the intervention works. Results may not apply to other groups or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 154 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2025

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 29 years

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Aim 1 (Formative Research and Beta-Testing) Transgender women Inclusion Criteria: * Ages between 18 and 29 years * Male sex at birth * Self-identifies as women, transgender women or culturally identifies with the female spectrum * Laboratory-confirmed HIV-negative status * Self-reported recent history of condomless sex * Able to understand, read and speak Thai * Either not started PrEP or currently on PrEP but not adherent (taking ≤3 pills/week) in the past month. Exclusion Criteria: * Have a serious cognitive or psychiatric problem compromising ability to provide informed consent * Have active suicidal ideation or major mental illness at the time of interview (these patients will be referred for treatment) * Laboratory or clinical findings that would preclude PrEP initiation (e.g., decreased creatinine clearance) * Currently enrolled in another HIV intervention study. Healthcare providers Inclusion criteria * Age 18 or above * Has provided HIV prevention or treatment services for TGW for at least one year Exclusion criteria * None Aim 2 (Pilot RCT) Transgender women Inclusion criteria * Ages between 18 and 29 years * Male sex at birth * Self-identifies as women, transgender women or culturally identifies with the female spectrum * Laboratory-confirmed HIV-negative status * Self-reported recent history of condomless sex * Able to understand, read and speak Thai * Either not started PrEP or currently on PrEP but not adherent (taking ≤3 pills/week) in the past month. Exclusion criteria * Have a serious cognitive or psychiatric problem compromising ability to provide informed consent * Have active suicidal ideation or major mental illness at the time of interview (these patients will be referred for treatment) * Laboratory or clinical findings that would preclude PrEP initiation (e.g., decreased creatinine clearance) * Currently enrolled in another HIV intervention study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pre-exposure prophylaxis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Social Stigma HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pre-exposure prophylaxis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Institute of HIV Research and Innovation

    RECRUITING

    Bangkok, Thailand

  • Rainbow Sky Association of Thailand

    RECRUITING

    Bangkok, Thailand

  • SWING Foundation

    RECRUITING

    Bangkok, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.